At a glance
- Originator Banyu
- Class Antiasthmatics; Bronchodilators
- Mechanism of Action Muscarinic M3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 21 Sep 1998 Preclinical development for Chronic obstructive pulmonary disease in Japan (Unknown route)